The Pharmacology Center

Filter Your Results




Primary Endpoint Met Early in COMPASS Study of Xarelto for CAD and PAD Patients

February 8, 2017 -- Bayer AG and its partner Janssen Research & Development, LLC announced that the phase 3 COMPASS trial has met its primary endpoint ahead of schedu…

Bleeding Avoidance Strategies

With Andrey Espinoza, MD, FACC, FSCAI; Paul A. Gurbel, MD; Sunil V. Rao, MD; and Steven J. Yakubov, MD, FACC, FSCAI

January/February 2017—Experts offer their experience with acute coronary syndrome protocol and how they approach access sites and handle bleeding events.

Meta-Analysis Evaluates CAS Before CABG

January 18, 2017 -- Online in the European Journal of Vascular and Endovascular Surgery (EJVES), Kosmas I. Paraskevas, MD, et al published a study on 30-day outcomes…

BioCardia Begins CardiAMP Pivotal Heart Failure Trial

January 3, 2017 -- BioCardia, Inc. announced the initiation of the CardiAMP Heart Failure pivotal trial. According to the company, the randomized controlled multicente…

EMIT-AF/VTE Registry Initiated to Evaluate Daiichi Sankyo's Lixiana

December 13, 2016 -- Daiichi Sankyo Europe GmbH announced that the first patient has been enrolled in the EMIT-AF/VTE registry, which will collect real-world clinical dat…

Study Finds Heparin Plus Short-Term Tirofiban Similar to Bivalirudin in Safety and Efficacy for PCI

November 17, 2016 -- A recent study has shown that two short-term blood clot prevention medications, heparin plus short-term tirofiban and bivalirudin, are both safe and effec…

PIONEER AF-PCI Results Presented for Xarelto in NVAF Patients After PCI With Stenting

November 14, 2016 -- Janssen Pharmaceuticals, Inc. announced new phase 3b results from the PIONEER AF-PCI study of the company’s Xarelto (rivaroxaban) compared to w…

Bivalirudin Compared With Unfractionated Heparin for PCI in STEMI Patients

November 11, 2016 -- Findings from a study conducted to describe temporal trends and determine the comparative effectiveness of bivalirudin versus unfractionated heparin (UFH)…



2017 Buyer’s Guide

This Buyer’s Guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007, with its launch issue focusing on the state of coronary drug-eluting stent use. Each edition will cover a variety of topics in a flexible format that includes articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's cardiology practices.